Small Molecules

24 May 2018 IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
23 May 2018 FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy
23 May 2018 Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
23 May 2018 Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform
23 May 2018 Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint
23 May 2018 HETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel
23 May 2018 Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease
23 May 2018 Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1
23 May 2018 PanOptica Doses First Patient with New Formulation of PAN-90806, a Novel, Topical Anti-VEGF Eye Drop, in Phase 1/2 Clinical Trial
23 May 2018 NeuroVive and Yungjin Reports Positive KL1333 Phase I Clinical Study Results Paving the way for Further Clinical Development
23 May 2018 Glenmark Pharmaceuticals Announces the Company's First New Drug Application for Ryaltris™ for Patients with Seasonal Allergic Rhinitis
23 May 2018 Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant
23 May 2018 Stanford Researchers Presented Results from an Exploratory Study of Serlopitant for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients Indicating Reduction in Itch with Serlopitant Treatment
23 May 2018 UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
23 May 2018 Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPD
23 May 2018 INSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray
22 May 2018 Nabriva Therapeutics Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia
22 May 2018 Dova Pharmaceuticals Announces U.S. FDA Approval of DOPTELET® (avatrombopag)
22 May 2018 FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes
22 May 2018 Lokelma approved in the US for the treatment of adults with hyperkalaemia
17 May 2018 European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma
17 May 2018 Clinical phase II results indicate that PMZ-2010 (centhaquin) is a novel highly effective resuscitative agent for hypovolemic shock
17 May 2018 Follow-Up Phase III Data Showed Genentech’s Alecensa Helped People With Alk-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death
17 May 2018 FDA Approves US WorldMeds' LUCEMYRA™ (lofexidine) After Priority Review for the Management of Opioid Withdrawal Symptoms
16 May 2018 Idorsia initiates MODIFY, a Phase 3 registration study to assess lucerastat as a potential new treatment option for patients with Fabry disease

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up